secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001193125-21-320325
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics files $350M ATM equity offering with Jefferies; terminates prior Leerink facility
--------------------------------------------------------------------------------

- Filed universal shelf registration on Form S-3ASR for common stock, preferred stock, debt securities, warrants, and units.
- Entered Open Market Sale Agreement with Jefferies to sell up to $350M of common stock in at-the-market offerings.
- Jefferies will receive a 3% commission on gross proceeds; company not obligated to sell any shares.
- Terminated prior at-the-market sales agreement dated November 21, 2018 with Leerink Partners effective upon filing.
- Either party may suspend or terminate the offering upon notice subject to conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312521320325/0001193125-21-320325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312521320325/d212515d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-320325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer